ImmuCell Corp (ICCC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$9.91+0.71%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Revenue growth after backorder clearance: 11.5% vs 13.9%.
ImmuCell is growing sales after clearing a big backorder. Revenue rose from $7.6M to $10.4M in Q1 2026. The company is expanding production for its First Defense product. This should support future growth.
ImmuCell is still losing money and has volatile management. Growth may slow after the backorder clears. Litigation and leadership changes add risks.
The market expects about 14% revenue growth next year. Our fair value is near $33, close to consensus. We see risk if growth slows more than expected.
Breaks if: Failure to convert facilities for First Defense by mid-2026
Breaks if: Further key management departures or execution failures in 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company has shown strong recent financial performance but is subject to high risks and management volatility, which adds uncertainty to its growth trajectory.
The current valuation is neutral, indicating that the market does not fully reflect the potential risks and uncertainties surrounding the company. There is a divergence in expectations, as the stock is seen as cheap compared to peers, but the overall premium suggests some caution.
Management is focused on expanding production capacity and increasing product sales, which have shown positive growth trends. However, there is a mixed outlook on revenue growth moderation following peak demand, which could impact future performance.
The thesis hinges on management's ability to execute on production capacity expansions and maintain sales growth. Additionally, external factors such as sector performance and economic conditions will play a crucial role in shaping the company's future.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company plans to expand First Defense production capacity. This expansion should significantly boost production. The recent earnings call showed record net income and market share. These factors support year-over-year sales growth. There are no new threats to the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: YoY revenue growth falls below 13.9% in FY26
Over the next 1 to 3 years, ICCC's performance will depend on management execution and external market conditions. Not investment advice.